3.連結財務諸表及び主な注記
(1)連結貸借対照表
|
|
|
|
|
|
|
|
|
|
|
|
(単位:千円)
|
|
|
|
|
|
|
|
|
|
|
|
前連結会計年度
(2025年3月31日)
|
当連結会計年度
(2026年3月31日)
|
|
資産の部
|
|
|
|
|
流動資産
|
|
|
|
|
|
現金及び預金
|
825,731
|
989,472
|
|
|
|
受取手形
|
7,021
|
4,990
|
|
|
|
売掛金
|
224,513
|
173,677
|
|
|
|
商品及び製品
|
42,608
|
69,861
|
|
|
|
仕掛品
|
144,680
|
170,996
|
|
|
|
原材料及び貯蔵品
|
130,466
|
138,867
|
|
|
|
その他
|
15,297
|
21,780
|
|
|
|
流動資産合計
|
1,390,318
|
1,569,646
|
|
|
固定資産
|
|
|
|
|
|
有形固定資産
|
|
|
|
|
|
|
建物及び構築物
|
792,710
|
811,857
|
|
|
|
|
|
減価償却累計額
|
△773,963
|
△775,672
|
|
|
|
|
|
建物及び構築物(純額)
|
18,747
|
36,184
|
|
|
|
|
機械装置及び運搬具
|
93,762
|
93,762
|
|
|
|
|
|
減価償却累計額
|
△70,768
|
△73,092
|
|
|
|
|
|
機械装置及び運搬具(純額)
|
22,993
|
20,669
|
|
|
|
|
土地
|
118,674
|
118,674
|
|
|
|
|
その他
|
556,991
|
516,363
|
|
|
|
|
|
減価償却累計額
|
△526,258
|
△486,421
|
|
|
|
|
|
その他(純額)
|
30,733
|
29,942
|
|
|
|
|
建設仮勘定
|
-
|
7,700
|
|
|
|
|
有形固定資産合計
|
191,148
|
213,171
|
|
|
|
無形固定資産
|
1,791
|
1,291
|
|
|
|
投資その他の資産
|
|
|
|
|
|
|
投資有価証券
|
95,058
|
170,058
|
|
|
|
|
繰延税金資産
|
112,338
|
145,412
|
|
|
|
|
その他
|
54,733
|
55,540
|
|
|
|
|
投資その他の資産合計
|
262,131
|
371,011
|
|
|
|
固定資産合計
|
455,071
|
585,475
|
|
|
資産合計
|
1,845,390
|
2,155,121
|
|
負債の部
|
|
|
|
|
流動負債
|
|
|
|
|
|
支払手形及び買掛金
|
3,720
|
2,992
|
|
|
|
短期借入金
|
140,000
|
142,000
|
|
|
|
1年内返済予定の長期借入金
|
29,136
|
16,417
|
|
|
|
未払法人税等
|
5,248
|
4,620
|
|
|
|
賞与引当金
|
33,950
|
34,101
|
|
|
|
その他
|
69,280
|
76,061
|
|
|
|
流動負債合計
|
281,335
|
276,194
|
|
|
固定負債
|
|
|
|
|
|
長期借入金
|
35,091
|
18,674
|
|
|
|
資産除去債務
|
3,740
|
3,772
|
|
|
|
退職給付に係る負債
|
10,863
|
13,106
|
|
|
|
固定負債合計
|
49,695
|
35,553
|
|
|
負債合計
|
331,031
|
311,747
|
|
純資産の部
|
|
|
|
|
株主資本
|
|
|
|
|
|
資本金
|
50,000
|
50,000
|
|
|
|
資本剰余金
|
1,040,407
|
1,040,407
|
|
|
|
利益剰余金
|
425,942
|
754,957
|
|
|
|
自己株式
|
△1,990
|
△1,990
|
|
|
|
株主資本合計
|
1,514,358
|
1,843,374
|
|
|
純資産合計
|
1,514,358
|
1,843,374
|
|
負債純資産合計
|
1,845,390
|
2,155,121
|
E00986
45700
株式会社免疫生物研究所
Immuno-Biological Laboratories Co., Ltd.
通期第1号参考様式 [日本基準](連結)
Japan GAAP
true
cte
cte
2025-04-01
2026-03-31
FY
2026-03-31
2024-04-01
2025-03-31
2025-03-31
1
false
false
false
45700
2026-05-13
45700
2025-04-01
2026-03-31
45700
2025-04-01
2026-03-31
jppfs_cor:CapitalStockMember
45700
2025-04-01
2026-03-31
jppfs_cor:CapitalSurplusMember
45700
2025-04-01
2026-03-31
jpcrp_cor:ReconcilingItemsMember
45700
2025-04-01
2026-03-31
jpcrp_cor:ReportableSegmentsMember
45700
2025-04-01
2026-03-31
jppfs_cor:RetainedEarningsMember
45700
2025-04-01
2026-03-31
jppfs_cor:ShareholdersEquityMember
45700
2025-04-01
2026-03-31
jppfs_cor:TreasuryStockMember
45700
2025-04-01
2026-03-31
tse-acedjpfr-45700:CosmeticsReportableSegmentsMember
45700
2025-04-01
2026-03-31
tse-acedjpfr-45700:ImmunityRelatedReportableSegmentMember
45700
2026-03-31
45700
2026-03-31
jppfs_cor:CapitalStockMember
45700
2026-03-31
jppfs_cor:CapitalSurplusMember
45700
2026-03-31
jpcrp_cor:ReconcilingItemsMember
45700
2026-03-31
jpcrp_cor:ReportableSegmentsMember
45700
2026-03-31
jppfs_cor:RetainedEarningsMember
45700
2026-03-31
jppfs_cor:ShareholdersEquityMember
45700
2026-03-31
jppfs_cor:TreasuryStockMember
45700
2026-03-31
tse-acedjpfr-45700:CosmeticsReportableSegmentsMember
45700
2026-03-31
tse-acedjpfr-45700:ImmunityRelatedReportableSegmentMember
45700
2024-04-01
2025-03-31
45700
2024-04-01
2025-03-31
jppfs_cor:CapitalStockMember
45700
2024-04-01
2025-03-31
jppfs_cor:CapitalSurplusMember
45700
2024-04-01
2025-03-31
jpcrp_cor:ReconcilingItemsMember
45700
2024-04-01
2025-03-31
jpcrp_cor:ReportableSegmentsMember
45700
2024-04-01
2025-03-31
jppfs_cor:RetainedEarningsMember
45700
2024-04-01
2025-03-31
jppfs_cor:ShareholdersEquityMember
45700
2024-04-01
2025-03-31
jppfs_cor:TreasuryStockMember
45700
2024-04-01
2025-03-31
tse-acedjpfr-45700:CosmeticsReportableSegmentsMember
45700
2024-04-01
2025-03-31
tse-acedjpfr-45700:ImmunityRelatedReportableSegmentMember
45700
2025-03-31
45700
2025-03-31
jppfs_cor:CapitalStockMember
45700
2025-03-31
jppfs_cor:CapitalSurplusMember
45700
2025-03-31
jpcrp_cor:ReconcilingItemsMember
45700
2025-03-31
jpcrp_cor:ReportableSegmentsMember
45700
2025-03-31
jppfs_cor:RetainedEarningsMember
45700
2025-03-31
jppfs_cor:ShareholdersEquityMember
45700
2025-03-31
jppfs_cor:TreasuryStockMember
45700
2025-03-31
tse-acedjpfr-45700:CosmeticsReportableSegmentsMember
45700
2025-03-31
tse-acedjpfr-45700:ImmunityRelatedReportableSegmentMember
45700
2024-03-31
45700
2024-03-31
jppfs_cor:CapitalStockMember
45700
2024-03-31
jppfs_cor:CapitalSurplusMember
45700
2024-03-31
jppfs_cor:RetainedEarningsMember
45700
2024-03-31
jppfs_cor:ShareholdersEquityMember
45700
2024-03-31
jppfs_cor:TreasuryStockMember
iso4217:JPY
xbrli:pure